Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2005 | Endotis | Series A | 4.9M |
5/2014 | Odoo | Series B | 10M |
5/2005 | Sefas Innovation | Venture Round | 3.8M |
9/2016 | Delinia | Series A | 35M |
1/2022 | SafeHeal | Venture Round | 0 |
9/2004 | Oxxius | Series A | 2.9M |
7/2010 | Mainstay Medical | Series A | 6.1M |
6/2007 | PregLem | Series A | 26M |
6/2019 | AFYX Therapeutics | Debt Financing | 13M |
10/2006 | Wyplay | Series A | 5.1M |
8/2008 | mydeco | Series A | 14.5M |
3/2016 | TISSIUM | Series A | 25.5M |
2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
4/2020 | Epsilen Bio | Seed Round | - |
7/2007 | Diatos | Series D | 12.8M |
11/2021 | Home Biosciences | Seed | 15M |
12/2007 | PregLem | Series B | 32.2M |
11/2016 | Corwave | Series B | 17.1M |
4/2022 | Prometheus Materials | Series A | 8M |
3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
8/2021 | TISSIUM | Series C | 59.1M |
7/2019 | Abivax | Post-IPO Equity | 13.5M |
4/2020 | EnginZyme | Series A | 6.9M |
4/2013 | MedDay | Series A | 10.5M |
10/2002 | Cobion | Venture Round | 5.9M |
8/2006 | Ablynx | Series C | 50M |
1/2016 | ENYO Pharma | Series A | 23.9M |
8/2000 | BioSpace | Series B | 10M |
9/2010 | Bee Ware | Series B | 5.6M |
12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
4/2022 | LimFlow SA | Series D | 0 |
12/2021 | Meiogenix | Series A | 12.4M |
5/2005 | Bee Ware | Series A | 3.8M |
3/2008 | Filao | Venture Round | 0 |
12/2007 | Ascendis Pharma | Series A | 25.7M |
3/2016 | CelluComp | Venture Round | 5.3M |
3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
3/2005 | Filao | Venture Round | 4.6M |
4/2014 | ProQR Therapeutics | Series A | 57.9M |
7/2020 | Enthera | Series A | 0 |
1/2006 | Blyk | Series A | 35.4M |
11/2021 | Synthace | Series C | 35M |
3/2018 | SafeHeal | Series A | 7.4M |
7/2020 | MISSION Therapeutics | Venture Round | 15M |
1/2007 | Stentys | Seed Round | - |
9/2013 | Synthace | Seed Round | 2.1M |
1/2010 | BioAmber | Series A | 0 |
7/2021 | protera | Series A | 0 |
10/2022 | Mablink Bioscience | Series A | 30.1M |
3/2009 | Neosens | Series B | 5.3M |
2/2008 | Neosens | Venture Round | 3.7M |
3/2007 | MXP4 | Series A | 6.5M |
5/2004 | Addex Therapeutics | Series B | 0 |
1/2004 | Infra Worlds | Series A | 1.7M |
5/2009 | MXP4 | Series B | 2.7M |
4/2020 | RefleXion Medical | Series D | 0 |
5/2023 | BrightHeart | Seed Round | 2.1M |
2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
9/2022 | Abivax | Post-IPO Equity | 0 |
11/2013 | Pixium Vision | Series A | 20.3M |
1/2023 | Amolyt Pharma | Series C | 0 |
1/2009 | DBV Technologies | Series B | 7.8M |
7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
1/2006 | DBV Technologies | Venture Round | 15.1M |
1/2008 | CrestaTech | Series A | 5M |
1/2005 | CrestaTech | Seed Round | 1.5M |
10/2011 | Hookipa Pharma | Series A | 9.6M |
3/2018 | Micropep Technologies | Series A | 5M |
1/2013 | ProQR Therapeutics | Seed Round | - |
4/2006 | Endoart | Series C | 0 |
2/2003 | Avaki | Series A | 4.2M |
3/2008 | Laszlo Systems | Series C | 14.6M |
4/2016 | MedDay | Series B | 0 |
4/2018 | Crescendo Biologics | Series B | 0 |
10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
12/2021 | DMC Biotechnologies | Series B | 0 |
12/2019 | DMC Biotechnologies | Series A | 0 |
5/2022 | GFBiochemicals | Series A | 0 |
11/2011 | NuCana BioMed | Series A | 10.5M |
12/2022 | EnginZyme | Series B | 22.3M |
2/2017 | Zyl | Venture Round | - |
7/2019 | AblaCare | Series A | 11.2M |
12/2016 | Hookipa Pharma | Series B | 10.7M |
12/2013 | Crescendo Biologics | Series A | 28.5M |
3/2017 | Biotalys | Series B | 0 |
12/2018 | Shockwave Medical | Series D | 0 |
1/2002 | Innate Pharma | Series B | 17.8M |
7/2007 | Inside Secure | Series B | 0 |
12/2007 | Fovea Pharmaceuticals | Series B | 30M |
4/2004 | Ablynx | Series B | 30M |
3/2000 | Innate Pharma | Series A | 4.4M |
3/2023 | Noema Pharma | Series B | 0 |
10/2006 | Domain Therapeutics | Series C | 10.4M |
3/2023 | Mediar Therapeutics | Series A | 0 |
12/2013 | Green Biologics | Series B | 0 |
7/2006 | Accent | Venture Round | 13.3M |
5/2019 | DNA Script | Series B | 38.5M |
1/2009 | Revolt Technology | Series B | 13.1M |
2/2008 | Ocera Therapeutics | Series C | 0 |
6/2021 | Borea Therapeutics | Seed Round | - |
6/2005 | Revolt Technology | Series A | 8.5M |
5/2015 | Twenga | Series A | 11M |
11/2003 | Esmertec AG | Series C | 0 |
10/1998 | BoostWorks | Series A | 3M |
12/2012 | Flexion Therapeutics | Series B | 20M |
8/2022 | F2G | Private Equity Round | 0 |
4/2008 | Qosmos | Series C | 10.8M |
1/2004 | Intransa | Series C | 8M |
2/2002 | Tak Imaging | Series B | 9.5M |
5/2010 | Crocus Technology | Series C | 0 |
11/2021 | GlycoEra | Series A | 0 |
1/2005 | VoluBill | Series C | 0 |
9/2019 | Inotrem | Series B | 43.1M |
10/2004 | Sensitive Object | Series A | 2.5M |
7/2021 | Artios Pharma | Series C | 0 |
4/2018 | LimFlow SA | Series C | 33.4M |
7/2007 | GlycoVaxyn | Series A | 9.5M |
7/2005 | Filao | Venture Round | 0 |
7/2021 | protera | Series A | 0 |
6/2019 | Comet Therapeutics | Series A | 28.5M |
7/2021 | Micropep Technologies | Series A | 10.1M |
9/2007 | Purple Labs | Series A | 12.7M |
4/2002 | Esmertec AG | Venture Round | 8.8M |
11/2002 | PhyFlex Networks | Series B | 0 |
2/2002 | Domain Therapeutics | Series A | 2.6M |
1/2019 | HighLife | Series B | 36M |
4/2013 | Aledia | Series A | 12.8M |
6/2022 | Micropep Technologies | Series A | 0 |
10/2010 | ASSIA | Series D | 20.8M |
7/2019 | Biotalys | Series C | 0 |
7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
6/2010 | QuesCom | Venture Round | 0 |
1/2007 | Movetis | Series A | 63.8M |
1/2003 | Intransa | Series B | 6M |
10/2009 | Flexion Therapeutics | Series A | 33M |
4/2020 | Pi-Cardia | Venture Round | 27M |
9/2017 | Synthace | Series A | 9.9M |
9/2017 | DNA Script | Series A | 13.2M |
3/2004 | UPEK | Series A | 20M |
3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
9/2002 | Ablynx | Series A | 4.9M |
11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
7/1999 | BoostWorks | Series B | 7M |
7/2002 | Addex Therapeutics | Series A | 9.9M |
10/2018 | Sitryx Therapeutics | Series A | 30M |
11/2021 | Nitrase Therapeutics | Series A | 0 |
5/2020 | HotSpot Therapeutics | Series B | 65M |
4/2005 | Tak Imaging | Series C | 10M |
1/2004 | Tak Imaging | Series C | 16.3M |
2/2013 | MetGen | Venture Round | 2.9M |
7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
6/2020 | Protera | Series A | 5.6M |
1/2005 | Biolipox | Series C | 41M |
3/2008 | Mobile Digital Media | Venture Round | 0 |
8/2004 | Intransa | Series D | 24M |
7/2019 | Comet Biorefining | Venture Round | - |
1/2015 | Green Biologics | Equity | 42M |
11/2006 | Abionyx Pharma | Series B | 53.5M |
12/2007 | Streamezzo | Series C | 22M |
2/2002 | Intransa | Venture Round | 10M |
4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
2/2016 | MISSION Therapeutics | Series C | 86.5M |
5/2010 | Noxxon Pharma | Series D | 40.7M |
2/2015 | Synthace | Venture Round | 3.4M |
11/2006 | CoreValve | Venture Round | 20M |
11/2018 | InCarda Therapeutics | Series B | 42M |
5/2004 | Domain Therapeutics | Series B | 19.1M |
7/2006 | GlycoVaxyn | Seed Round | - |
3/2014 | Inotrem | Series A | 25.1M |
10/2009 | Crescendo Biologics | Seed Round | 0 |
1/2018 | Aledia | Series C | 0 |
5/2007 | Noxxon Pharma | Series C | 50.2M |
4/2018 | Erydel | Series B | 32.4M |
4/2014 | RefleXion Medical | Series A | 11.6M |
5/2014 | Avantium | Series G | 0 |
9/2020 | POLYNEURON | Series A | 15.4M |
11/2014 | myTomorrows | Venture Round | 5.6M |
4/2014 | Crescendo Biologics | Series A | 3.3M |
10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
2/2012 | BioAmber | Series C | 0 |
10/2017 | HighLife | Series A | 14.3M |
7/2018 | HotSpot Therapeutics | Series A | 45M |
5/2018 | Biosyntia | Series A | 4.7M |
3/2009 | GlycoVaxyn | Series B | 21.4M |
10/2011 | Creabilis | Series B | 20M |
4/2006 | Varioptic | Series C | 0 |
6/2015 | Aledia | Series B | 0 |
11/2019 | TISSIUM | Series B | 43.2M |
6/2018 | Castle Biosciences | Venture Round | 0 |
7/2019 | Microphyt | Venture Round | 31.9M |
4/2020 | Nitrase Therapeutics | Series A | 38M |
6/2009 | blueKiwi software | Series B | 0 |
4/2015 | ReCor Medical | Series D | 15M |
1/2008 | TAK imaging | Series C | 16.2M |
6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
9/2006 | Addex Therapeutics | Series C | 0 |
1/2003 | Biolipox | Series B | 21M |
9/2002 | EnvoyWorldWide | Series C | 4.5M |
7/2022 | Biosyntia | Series B | 11.7M |
3/2008 | Stentys | Series A | 18M |
1/2007 | blueKiwi software | Series A | 5.3M |
12/2021 | EndoRon Medical | Seed Round | 5M |
2/2019 | AFYREN | Venture Round | 23.8M |
2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
2/2021 | Mainstay Medical | Private Equity Round | 0 |
6/2018 | NodThera | Series A | 40M |
10/2021 | Leucid Bio | Series A | 15.9M |
7/2021 | Muna Therapeutics | Series A | 0 |
1/2011 | DBV Technologies | Series C | 25.5M |
4/2016 | RefleXion Medical | Series B | 52M |
5/2019 | CinCor Pharma | Series A | 50M |
3/2004 | Varioptic | Series B | 12.2M |
5/2009 | Streamezzo | Series D | 5.5M |
4/2014 | NuCana | Series B | 0 |
10/2003 | Cotherix | Series C | 55M |
4/2018 | RefleXion Medical | Series C | 100M |
2/2016 | Corvidia | Series A | 26M |
7/2021 | Comet Biorefining | Series C | 0 |
9/2004 | Innate Pharma | Series C | 0 |
1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
4/2006 | Streamezzo | Series B | 0 |
7/2010 | Abionyx Pharma | Series C | 0 |
6/2021 | Mnemo Therapeutics | Series A | 90M |
10/2016 | MD Start | Venture Round | 0 |
6/2013 | MetGen | Series A | - |
3/2017 | Comet Biorefining | Venture Round | - |
11/2016 | Shockwave Medical | Series C | 45M |
4/2018 | EnobraQ | Seed Round | 3.6M |
6/2021 | Alia Therapeutics | Seed Round | - |
11/2013 | Hookipa Pharma | Series B | 27M |
6/2016 | DNA Script | Seed Round | 2.8M |
3/2017 | Breath Therapeutics | Series A | 45.9M |
3/2007 | CoreValve | Series C | 33M |
8/2005 | Abionyx Pharma | Series A | 30.5M |
12/2017 | Hookipa Pharma | Series C | 0 |
11/2020 | Catamaran Bio | Series A | 0 |
5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
11/2003 | Saegis Pharmaceuticals | Series B | 30M |
12/2020 | Noema Pharma | Series A | 60M |
1/2008 | Inside Secure | Series C | 0 |
3/2023 | BioCorteX | Seed Round | 0 |
1/2017 | myTomorrows | Venture Round | 10.6M |
3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
6/2020 | NodThera | Series B | 55M |
9/2016 | IOmx Therapeutics | Series A | 44.6M |
10/2021 | IOmx Therapeutics | Series B | 0 |
4/2018 | Corvidia | Series B | 60M |
5/2020 | CorVent Medical | Seed Round | 0 |
2/2023 | Abivax | Post-IPO Equity | 0 |
5/2015 | Shockwave Medical | Series B | 40M |
2/2006 | Lectus Therapeutics | Series A | 14.3M |
4/2005 | Laszlo Systems | Series B | 6.3M |
9/2007 | VoluBill | Series D | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
2/2010 | Odoo | Series A | 4.1M |
3/2023 | Chroma Medicine | Series B | 0 |
11/2021 | HotSpot Therapeutics | Series C | 0 |
9/2006 | Qosmos | Series B | 4.1M |
10/2021 | Mozart Therapeutics | Series A | 0 |
11/2013 | MISSION Therapeutics | Series B | 32.2M |
8/2011 | MISSION Therapeutics | Series A | 6M |
7/2018 | Enthera | Seed Round | 4.7M |
11/2013 | CelluComp | Seed Round | 3.9M |
4/2020 | Pyrowave | Series B | - |
1/2021 | Corwave | Series C | 43.2M |
1/2014 | Shockwave Medical | Series A | 12.5M |
6/2021 | AAVantgarde Bio | Seed Round | - |
2/2015 | Comet Biorefining | Venture Round | - |
6/2022 | Moon Surgical | Series A | 31.3M |
2/2022 | Elicit Plant | Series A | 18.3M |
4/2013 | Auris Medical | Series C | 51M |
1/2002 | EnvoyWorldWide | Series B | 8M |
1/2003 | Varioptic | Series A | 2.1M |
3/2017 | HotSpot Therapeutics | Seed Round | - |
2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
11/2020 | Myricx Pharma | Seed Round | 5.9M |
12/2009 | Sensitive Object | Series B | 6M |
3/2019 | POLYNEURON | Series A | 22.6M |
10/2021 | Sphere Fluidics | Venture Round | 41.4M |
9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
11/2015 | ObsEva | Series B | 58.9M |
4/2020 | Genespire | Series A | 17.4M |
9/2015 | Asceneuron | Series A | 30.8M |
11/2011 | NuCana | Series A | 0 |
6/2008 | Creabilis | Series A | 31.4M |
9/2006 | Oxxius | Series B | 10M |
4/2005 | TAK imaging | Series C | 10M |
11/2022 | Microphyt | Series B | 0 |
5/2023 | BrightHeart | Seed Round | 0 |
5/2023 | TISSIUM | Series D | 0 |
5/2023 | Moon Surgical | Series B | 0 |
5/2023 | Werewool | Seed Round | 0 |
4/2023 | Alia Therapeutics | Seed Round | 0 |
3/2023 | BioCorteX | Seed Round | 0 |
3/2023 | deepc | Series A | 0 |
3/2023 | Kiro | Series A | 0 |
3/2023 | Mediar Therapeutics | Series A | 0 |
3/2023 | Noema Pharma | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|